Last reviewed · How we verify

NCT04635306

13C-Spirulina Nitrogen Content GEBT Study

Terminated NA Last updated 3 August 2021
What this trial tests

NA trial testing Approved GEBT test meal in Gastroparesis in 12 participants. Terminated before completion.

Timeline
21 October 2020
Primary endpoint
25 June 2021
25 June 2021

Quick facts

Lead sponsorCairn Diagnostics
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment12
Start date21 October 2020
Primary completion25 June 2021
Estimated completion25 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cairn Diagnostics — full company profile →

Who can join

Adults 18 to 85, any sex, with Gastroparesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether there is a difference in the human in vivo response to 13C-Spirulina meals manufactured using 13C-Spirulina containing different levels of protein (as measured by %nitrogen).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Unlocking the potential of microalgae-derived therapeutic carriers: Characteristics, types, and nanomedical applications.
    Wang P, Liu C, Zheng L. · · 2025 · cited 7× · PMID 40688659 · DOI 10.1016/j.mtbio.2025.102037

Verify or expand the search:

Other recruiting trials for Gastroparesis

Currently open trials in the same condition.

Other Cairn Diagnostics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04635306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing